SCHEMBL5546798

SCHEMBL5546798

O=C(NCCO)c1c(O)c2ncc(Cc3ccc(F)cc3C(F)(F)F)cc2[nH]c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
TDP1 Q9NUW8 1/20 0.36
GCGR P47871 2/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
NPC1 O15118 1/20 0.35
PKM P14618 1/20 0.35
RAB9A P51151 1/20 0.35
GSK3B P49841 1/20 0.34
P2RX7 Q99572 2/20 0.33
KDM5A P29375 1/20 0.33
ALPL P05186 1/20 0.33
MAPK1 P28482 1/20 0.33
EPHX2 P34913 1/20 0.33
PPARG P37231 1/20 0.33
RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538964 0.95 HDAC3 (0.36) GPR52HDAC3HDAC1HDAC2HDAC6
SCHEMBL5540956 0.91 TDP1 (0.40) HDAC3HDAC1HDAC2HDAC6TDP1
SCHEMBL5546928 0.88 TDP1 (0.36) HDAC3HDAC1HDAC2HDAC6TDP1
SCHEMBL5545421 0.87 PARP1 (0.47)
SCHEMBL5538646 0.85 TDP1 (0.47) GPR52TDP1MEN1KMT2ANPC1
SCHEMBL5547490 0.85 HDAC3 (0.37) HDAC3HDAC1HDAC2HDAC6TDP1
SCHEMBL5545347 0.85 KDM4E (0.51) KMT2ARAB9A
SCHEMBL6061942 0.80 TDP1 (0.46) TDP1MEN1KMT2ANPC1PKM
SCHEMBL5545745 0.80 TDP1 (0.42) TDP1MEN1KMT2AGSK3BKDM5A
SCHEMBL5539148 0.79 TDP1 (0.38) TDP1MEN1KMT2AGSK3BKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 GPR52 2290/4885HDAC3 281/4885HDAC1 252/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 GPR52 3391/4885HDAC3 1219/4885HDAC1 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.